

Rosario Perona

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3819415/rosario-perona-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38

papers

1,262

citations

16

h-index

35

g-index

42

ext. papers

1,379

ext. citations

6.1

avg, IF

3.83

L-index

#	Paper	IF	Citations
38	Evidence of telomere attrition and a potential role for DNA damage in systemic sclerosis.. <i>Immunity and Ageing</i> , 2022 , 19, 7	9.7	0
37	Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities.. <i>Cells</i> , 2022 , 11,	7.9	1
36	Choline Kinase Inhibitors MN58b and RSM932A Enhances the Antitumor Response to Cisplatin in Lung Tumor Cells. <i>Pharmaceutics</i> , 2022 , 14, 1143	6.4	
35	GSE4-loaded nanoparticles a potential therapy for lung fibrosis that enhances pneumocyte growth, reduces apoptosis and DNA damage. <i>FASEB Journal</i> , 2021 , 35, e21422	0.9	4
34	Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells. <i>Oncolmmunology</i> , 2020 , 9, 1773204	7.2	6
33	Structure of Dictyostelium discoideum telomeres. Analysis of possible replication mechanisms. <i>PLoS ONE</i> , 2019 , 14, e0222909	3.7	2
32	GSE4 peptide suppresses oxidative and telomere deficiencies in ataxia telangiectasia patient cells. <i>Cell Death and Differentiation</i> , 2019 , 26, 1998-2014	12.7	13
31	Role of Dusp6 Phosphatase as a Tumor Suppressor in Non-Small Cell Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	11
30	Dyskerin Mutations Present in Dyskeratosis Congenita Patients Increase Oxidative Stress and DNA Damage Signalling in. <i>Cells</i> , 2019 , 8,	7.9	3
29	High expression of MKP1/DUSP1 counteracts glioma stem cell activity and mediates HDAC inhibitor response. <i>Oncogenesis</i> , 2017 , 6, 401	6.6	16
28	Molecular Diagnosis and Precision Therapeutic Approaches for Telomere Biology Disorders 2016 ,		2
27	c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2780-2790	6.1	8
26	Development of surface modified biodegradable polymeric nanoparticles to deliver GSE24.2 peptide to cells: a promising approach for the treatment of defective telomerase disorders. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015 , 91, 91-102	5.7	22
25	GSE4, a Small Dyskerin- and GSE24.2-Related Peptide, Induces Telomerase Activity, Cell Proliferation and Reduces DNA Damage, Oxidative Stress and Cell Senescence in Dyskerin Mutant Cells. <i>PLoS ONE</i> , 2015 , 10, e0142980	3.7	9
24	Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations. <i>International Journal of Clinical and Experimental Pathology</i> , 2015 , 8, 2888-98	1.4	7
23	Development and validation of a rapid HPLC method for the quantification of GSE4 peptide in biodegradable PEI-PLGA nanoparticles. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014 , 972, 95-101	3.2	4
22	Expression of the genetic suppressor element 24.2 (GSE24.2) decreases DNA damage and oxidative stress in X-linked dyskeratosis congenita cells. <i>PLoS ONE</i> , 2014 , 9, e101424	3.7	15

21	Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. <i>Cancer Medicine</i> , 2014 , 3, 1099-111	4.8	57
20	Targeted Cargo Delivery in Senescent Cells Using Capped Mesoporous Silica Nanoparticles. <i>Angewandte Chemie</i> , 2012 , 124, 10708-10712	3.6	14
19	Targeted cargo delivery in senescent cells using capped mesoporous silica nanoparticles. <i>Angewandte Chemie - International Edition</i> , 2012 , 51, 10556-60	16.4	97
18	Defects in mTR stability and telomerase activity produced by the Dkc1 A353V mutation in dyskeratosis congenita are rescued by a peptide from the dyskerin TruB domain. <i>Clinical and Translational Oncology</i> , 2012 , 14, 755-63	3.6	10
17	The dual-specificity protein phosphatase MkpB, homologous to mammalian MKP phosphatases, is required for <i>D. discoideum</i> post-aggregative development and cisplatin response. <i>Differentiation</i> , 2011 , 81, 199-207	3.5	3
16	A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. <i>Clinical and Translational Oncology</i> , 2011 , 13, 289-93	3.6	57
15	Treatment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. <i>Clinical and Translational Oncology</i> , 2011 , 13, 774-9	3.6	3
14	Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin. <i>Clinical Cancer Research</i> , 2009 , 15, 3530-9	12.9	50
13	Telomerase deficiency and cancer susceptibility syndromes. <i>Clinical and Translational Oncology</i> , 2009 , 11, 711-4	3.6	9
12	MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. <i>Cancer Letters</i> , 2009 , 286, 206-16	9.9	19
11	Molecular Biology of Malignant Gliomas 2009 , 1-22		
10	A dyskerin motif reactivates telomerase activity in X-linked dyskeratosis congenita and in telomerase-deficient human cells. <i>Blood</i> , 2008 , 111, 2606-14	2.2	19
9	Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach. <i>Clinical and Translational Oncology</i> , 2008 , 10, 73-7	3.6	21
8	The role of the NFkappaB signalling pathway in cancer. <i>Clinical and Translational Oncology</i> , 2008 , 10, 143-7	3.6	46
7	Role of CHK2 in cancer development. <i>Clinical and Translational Oncology</i> , 2008 , 10, 538-42	3.6	28
6	Molecular biology of malignant gliomas. <i>Clinical and Translational Oncology</i> , 2006 , 8, 635-41	3.6	26
5	Regulation of Cu/Zn-superoxide dismutase expression via the phosphatidylinositol 3 kinase/Akt pathway and nuclear factor-kappaB. <i>Journal of Neuroscience</i> , 2004 , 24, 7324-34	6.6	168
4	Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. <i>Molecular Biology of the Cell</i> , 2002 , 13, 2933-45	3.5	89

- 3 CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin. *Oncogene*, **2000**, 19, 5142-52 122
- 2 Lack of c-Jun activity increases survival to cisplatin. *FEBS Letters*, **1999**, 453, 151-8 3.8 84
- 1 Cisplatin induces a persistent activation of JNK that is related to cell death. *Oncogene*, **1998**, 16, 533-40 9.2 210